• Klaria Pharma will issue 46,294,165 series TO1 warrants alongside 185,176,660 new shares through its rights issue.
• Total proceeds reach approximately SEK 111.1 million before costs, including SEK 37.3 million through debt offsets.
• Each TO1 warrant entitles holders to subscribe for one share at SEK 0.60 during five exercise periods spanning November 2027–October 2029.
• Full warrant exercise could raise approximately SEK 27.8 million before costs, resulting in additional dilution of approximately 9.7%.
• Registration is expected around November 24, 2026; TO1 trading on Nasdaq First North Growth Market is targeted for November 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202611131245BITN____UKPR__SV_20261113-BIT-9098-0) on November 13, 2026, and is solely responsible for the information contained therein.